The nuclear expression of beta-catenin as a prognostic marker of sporadic desmoid tumors with meloxicam

The nuclear expression of beta-catenin as a prognostic marker of sporadic desmoid tumors with meloxicam - The nuclear expression of beta-catenin as a prognostic marker of sporadic desmoid tumors with meloxicam

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019320

Enrollment

Registered

2015-10-13

Start date

2003-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sporadic desmoid tumor

Interventions

Meloxicam was administered orally at 10 mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with extra abdominal, sporadic desmoid tumors were treated with meloxicam as a systemic medical therapy

Exclusion criteria

Exclusion criteria: familial adenomatous polyposis-associated desmoid tumor

Design outcomes

Primary

Measure	Time frame
beta-catenin nuclear positivity efficacy of meloxicam treatment	—

Countries

Japan

Contacts

Public ContactShunsuke Hamada

Nagoya University Graduate School and School of Medicine Department of Orthopaedic Surgery

shamada@med.nagoya-u.ac.jp052-744-1908

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026